| Patient | Mildred Ella Didrikson Zaharias |
|---|---|
| Date of birth | 1911-06-26 |
| Identifiers | MRN HR-ML038-SYN-TD; SSN (made up) 000-38-4471 |
| Document date | 1953-04-27 |
| Author | Rosalind Vasquez-Thornbury, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Day 1 of cycle 2 of dostarlimab. [S]
Ms. Didrikson Zaharias comes before her second dose of dostarlimab. The first dose three weeks ago caused no reaction. Within ten days the bleeding became occasional streaks, and for the last week there has been none; her stools are a normal shape and the urgency has eased. She has had no diarrhea, rash, cough, breathlessness, headache or thirst. She has taken ferrous sulfate every other morning for four weeks, with mild constipation that settled with more fruit, and she is less tired. She is practicing every day and played 18 holes twice last week. The germline panel was negative, and tumor sequencing found two changes in MSH2 in the tumor itself, which explains the mismatch repair deficiency. She asked what this means for her brothers and sisters. [S]
| Element | Detail |
|---|---|
| Treatment | Dostarlimab cycle 1 three weeks ago; cycle 2 today |
| Symptoms | No bleeding for a week; normal stools; less tired |
| Adverse events | None |
| Genetic results | Germline panel negative; two somatic MSH2 variants in the tumor |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy better; no fever; weight 63.2 kg |
| Gastrointestinal | Negative | No bleeding for a week; no diarrhea or abdominal pain; mild constipation from iron, settled |
| Integumentary | Negative | No rash or itching |
| Respiratory | Negative | No cough or breathlessness |
| Endocrine | Negative | No heat or cold intolerance, thirst or headache |
| Psychiatric | Negative | Hopeful; PHQ-9 4; no thoughts of self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other morning | One tablet every other morning | Oral route | 1953-03-30 | active | S |
| Dostarlimab-gxly 50 mg/mL injection, 500 mg intravenously over 30 minutes every 3 weeks, for nine doses (six months) | 500 mg every 3 weeks for nine doses | Intravenous route | 1953-04-06 to 1953-09-21 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1953-04-27 | Body height | 168 | cm | S |
| 1953-04-27 | Body weight | 63.2 | kg | S |
| 1953-04-27 | Body mass index (BMI) [Ratio] | 22.4 | kg/m2 | S |
| 1953-04-27 | Systolic blood pressure | 110 | mm[Hg] | S |
| 1953-04-27 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1953-04-27 | Heart rate | 70 | /min | S |
| 1953-04-27 | Respiratory rate | 14 | /min | S |
| 1953-04-27 | Body temperature | 36.6 | Cel | S |
| 1953-04-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1953-04-27 | Hemoglobin [Mass/volume] in Blood | 12.1 | g/dL | 12-15.5 g/dL | Normal | S |
| 1953-04-27 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 80 | fL | 80-100 fL | Normal | S |
| 1953-04-27 | Leukocytes [#/volume] in Blood by Automated count | 6.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1953-04-27 | Platelets [#/volume] in Blood by Automated count | 352 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1953-04-27 | Creatinine [Mass/volume] in Serum or Plasma | 0.74 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1953-04-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1948)/1.73 sq M | 104 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1953-04-27 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-99 mg/dL | Normal | S |
| 1953-04-27 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-35 U/L | Normal | S |
| 1953-04-27 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 8-35 U/L | Normal | S |
| 1953-04-27 | Thyrotropin [Units/volume] in Serum or Plasma | 2.2 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 1953-04-27 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.2 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 1953-04-27 | Carcinoembryonic Ag [Mass/volume] in Serum or Plasma | 3.4 | ng/mL | Up to 3.0 ng/mL in non-smokers | High | S |
| 1953-04-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S |
Vital signs recorded on 1953-04-27; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 63.2 kg; blood pressure 110/68, pulse 70 |
| Skin | No rash |
| Neck | Thyroid not enlarged or tender |
| Abdomen | Soft, non-tender |
| Rectal | With her agreement and a chaperone: the mass is smaller and softer, with a flatter edge; no blood on the glove |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bright red blood with bowel movements for about three months, with narrower stools, urgency, a feeling of incomplete emptying, and a firm, ulcerated mass felt on the back wall of the lower rectum at about 5 cm from the anal verge: a rectal cancer must be confirmed or excluded. Colonoscopy with biopsy booked this week | resolved | confirmed | K62.5 | S — Synthetic presenting problem anchored to the documented fatigue before her cancer diagnosis. Superseded by the diagnosis at the second visit. |
| Iron deficiency anemia from chronic rectal blood loss: hemoglobin 11.0 g/dL, MCV 77 fL, ferritin 9 ng/mL, with tiredness | active | confirmed | D50.0 | S — Synthetic finding anchored to the documented fatigue at the end of the 1952 season. |
| Adenocarcinoma of the low rectum, mismatch repair deficient (loss of MSH2 and MSH6; microsatellite instability high), cT3bN1M0 (stage IIIB) on pelvic MRI, lower edge 4 cm from the anal verge and about 1 cm above the anorectal junction, mesorectal fascia clear, no extramural venous invasion; CEA 5.8 ng/mL; synthetic modern detail linked to her documented cancer, whose site the sources do not record exactly | active | confirmed | C20 | S — Synthetic histology, site, stage, mismatch repair status and course; the sources say she had cancer treated with a colostomy and call it colon cancer (R on the site). See sources.md. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count | Before each dose of dostarlimab and at each visit; about four weeks after oral iron starts | Completed today | Four weeks after oral iron: hemoglobin 12.1 g/dL, MCV 80 fL, white cells 6.2, platelets 352 |
| Laboratory | Kidney and liver function and glucose | Before each dose of PD-1 blockade | Completed today | Creatinine 0.74 mg/dL, eGFR 104; ALT 22 U/L, AST 24 U/L; glucose 92 mg/dL |
| Laboratory | TSH and free T4 | At baseline, then every six weeks on PD-1 blockade; six weeks after any levothyroxine change | Completed today | TSH 2.2 mIU/L, free T4 1.2 ng/dL |
| Laboratory | CEA | During treatment, as a marker of response | Completed today | 3.4 ng/mL, down from 5.8 |
| Examination | Digital rectal examination | At each oncology visit during treatment; every three to four months in watch-and-wait | Completed today | Mass smaller and softer; no blood |
| Examination | Immune-related adverse event review (diarrhea, rash, cough, breathlessness, fatigue, endocrine symptoms) | Before each dose | Completed today | None |
| Laboratory | Germline multigene panel and tumor sequencing | Germline result before treatment decisions that depend on it; tumor sequencing when the germline panel is negative | Completed today | Germline negative; two somatic MSH2 variants in the tumor; KRAS, NRAS and BRAF wild type |
| Self-management | Screening advice for first-degree relatives | Once the genetic results are known | Completed today | Colonoscopy from 40, or 10 years before her age at diagnosis if earlier, every five years; letter given for her to share as she chooses |
| Laboratory | Hepatitis B, hepatitis C and HIV screening | Before systemic cancer treatment | Up to date | All negative; hepatitis B surface antibody negative, so vaccination is due |
| Laboratory | Ferritin after oral iron | About three months after starting | Due | Due at the restaging visit |
| Imaging | Restaging pelvic MRI and flexible sigmoidoscopy | About every three months during treatment | Due | Booked for the week before cycle 5 |
| Survey | Distress and depression screen (PHQ-9, GAD-7) | At diagnosis, at each treatment phase, and at least yearly | Completed today | PHQ-9 4; item 9 scored 0 |
| Self-management | Physical activity and sport | Each visit | Completed today | Playing 18 holes and practicing daily |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (current version); summarized in Benson AB, et al. NCCN Guidelines Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw 2024;22(6):366-375 (PMID 39151454) (2026); Cercek A, et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med 2022;386(25):2363-2376 (PMID 35660797) (2022); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); Tung N, et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol 2024;42(21):2599-2615 (PMID 38759122) (2024); Rex DK, et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 2017;112(7):1016-1030 (PMID 28555630) (2017); CMID: Clinical Monitoring Intelligence Database, colorectal cancer, hypothyroidism and anemia monographs (2026)
Follow-up: Cycles 3 and 4 as booked; restaging MRI and sigmoidoscopy in about eight weeks; primary care review at cycle 5. Next scheduled visit 1953-06-29: restaging after four doses: pelvic MRI and endoscopy, immune-related hypothyroidism, and the decision to continue PD-1 blockade. [S]